World Bank nod for $477 million loan for health infra in Telangana
The bank will extend the loan to the state government under the 'Telangana Strategic Vision for Attaining Sustainable Transformation in Healthcare' project. Sources said that the appraisal of the loan will be in November 2025. Its final approval is expected in February 2026. The state Health, Medical and Family Welfare department (DoHMFW) will act as the implementing agency.
The total cost of implementing the project is $1,380.19 million, of which $477 million will be financed by the World Bank. The remaining $904.19 million will be contributed by the state.
The proposed programme has identified four entities, namely DoHMFW, Commissioner of Health and Family Welfare, Director of Public Health, and Director of Medical Education, to which the result areas will be linked. The budget lines aligned with programme objectives were identified to define the government programme, valued at $4.9 billion over a six-year period.
New OGH among infra projects
A subset of these expenditure categories — covering the delivery of primary, secondary, and tertiary health services; reproductive, maternal, newborn, and adolescent health (RMNCH); non-communicable diseases (NCDs); and the supply of medicines — was used to define the proposed programme, valued at $1.38 billion over six years. This represents 28 per cent of the overall government programme.
The cost estimate for the proposed programme includes 14 components: trauma care centres; dialysis centres; vascular access centres; simulation and skill labs for emergency care; integrated quality control laboratories; enhancement of diagnostic services; organ retrieval and storage centres (including burn centres and skin and cornea banks); improvements in specialised maternal and child health (MCH) services, including the Arogya Mahila programme and cochlear implant centres; drug de-addiction centres; TIMS and super-specialty hospital equipment; equipment for the new Osmania Hospital; health cards and project management units (PMU); and cancer care services.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
3 hours ago
- Time of India
Med camp for workers at treatment plant
Ludhiana: A health camp for workers was organised at the site of the water treatment plant (WTP) in Sahnewal's Bilga village Sunday. A total of 142 labourers/workers underwent general health and eye check-ups at the camp. The check-ups were done by a specialist team from community health centre, Sahnewal. It was led by doctors Kavita Kamal and Namrata. Ensuring full compliance with health and safety protocols, the initiative aimed to ensure the well-being of on-site workers through early diagnosis and preventive care. The camp was organised by the social safeguard and health and safety departments of Ludhiana Urban Water and Wastewater Management Ltd and the contractor firm. The world-class WTP is being set up as part of the World Bank-funded canal-based water supply project for Ludhiana city.
The Wire
2 days ago
- The Wire
Antibiotics, Diabetes and BP Drugs, Vitamin Supplements Found to Be Not of Standard Quality in June
Health Banjot Kaur Issues that Union and state regulators detected during their monthly inspections include contamination and incorrect labelling. Representative image of tablet drugs. Photo: New Delhi: Batches of as many as 185 drugs were found to be not of standard quality (NSQ) by Union and state drug regulators during their monthly inspection in June. The results of their inspections were released on Friday (July 18). A drug is labelled NSQ if it does not meet the quality standards laid down in the Indian laws governing drugs. The Central Drugs Standard Control Organisation (CDSCO) found batches of 55 drugs NSQ, with batches of the remaining 130 being flagged by various state drug regulators. The CDSCO is India's drug regulator at the Union government level. This is not a one-off list. It is a monthly document that the CDSCO publishes. The exercise became regular about a year ago. 'As part of the continuous regulatory surveillance, drug samples are picked from sales/distribution point and analysed, and the list of spurious [NSQ] drugs are displayed on the CDSCO portal on a monthly basis,' the CDSCO said. The purpose of displaying the list is to make stakeholders aware about the NSQ batches identified in the market, it added. The drugs that the CDSCO and state regulators most commonly found to be NSQ were mainly antibiotics, vitamin and calcium supplements, and anti-hypertensives (used for controlling blood pressure) in oral and injectable forms. The companies mentioned in this article are not the only ones whose products were found to be NSQ. We have only considered companies that made either multiple batches of a given drug that were found sub-par, or those that have manufactured various drugs that were found sub-par. It must be mentioned here that the CDSCO's and the states' labs only test a certain batch(es) of a particular medicine. If one batch of any drug has been red-flagged, it does not necessarily mean that all its batches would be substandard. Common 'errors' One of the most serious risks associated with NSQ drugs is improper sterility. This means that the drug contains harmful microorganisms that can lead to infection in a patient's body after ingestion. This could potentially cause extremely serious complications in patients, like sepsis or even death due to acute infection. The other common problem that some drugs have is that they contain 'particulate matter' – particles that inadvertently enter the drug during the manufacturing process. These particles can contaminate the drug. A 'description' error is one in which a drug's physical appearance does not match its prescribed appearance as per regulation. For example, if a tablet is described in regulation as having a white colour but a patient finds it to be orange, the tablet would have a description error. Several medicines were reported as experiencing 'loss on drying'. This error reflects the lack of moisture in drugs, which may cause microbial growth in them, potentially causing infection if ingested. A drug is labelled as having assay errors when an ingredient in it is found in a quantity that is higher or lower than what is mentioned on its label. A higher amount would mean an overdose and a lower amount would result in an underdose – the latter would lead to a situation where a patient even after consuming the prescribed strength of a drug ends up ingesting a lower quantity of some ingredient. This can lead to their disease getting worse. 'Extractable volume' errors usually occur with vials. If the liquid that is to be extracted from a vial using a syringe is present in a quantity greater or lower than as labelled, this can again lead to an overdose or underdose of the drug given in injectable form. 'Dissolution' errors can adversely affect the absorption of a drug. What did the CDSCO find? Six drugs manufactured by Paksons Pharmaceuticals Private Limited were found to be NSQ. These include a dexamethasone sodium phosphate injection – an antibiotic; an ascorbic acid injection, used as a vitamin C supplement; an adrenaline bitartrate injection, used during cardiac arrest; an ondansetron injection, used for treating nausea caused by cancer medicines; and a gentamicin injection, used for treating bacterial injections. The company's diclofenac sodium injection, used as a pain killer, had extractable volume issues in its vials. Four batches of Phaex Polymers Private Limited's colestyramine (used to treat high cholesterol) and three batches of its sodium polystyrene sulfonate (for regulating potassium levels) reported 'loss of drying' mistakes. Zee Laboratories' tranexamic acid injection, used for controlling excessive loss of blood during surgery in patients suffering from hemophilia, reported assay problems. On the other hand, its glipizide & metformin tablets, used for treating high blood sugar, had a description error. Two batches of Overseas Health Care Pvt Ltd's calcium aspartate, calcium orotate, calcitriol minerals and vitamin tablets, which are used to supplement calcium and micronutrients like zinc and vitamins to treat deficiencies, had compromised assays for almost all of their ingredients. Martin & Brown BioSciences Pvt Ltd's calcium gluconate injection had particulate matter and description errors along with extractable volume issues. Three batches of its rabeprazole sodium injection – used to treat acid reflux – also had particulate matter and assay problems. Two batches of E.G. Pharmaceuticals' vitamin C injection and vitamin B12, folic acid and niacinamide injection had particulate matter and description errors. Two batches of Healers Lab's telmisartan tablets (used to manage blood pressure) had dissolution issues. What did state drug regulators find? State drug regulators too found serious errors in some drugs. Five batches of Puniska Injectables's sodium chloride injection had serious sterility problems. These injections have multiple purposes. They are primarily given in cases of dehydration to restore electrolytes (sodium and chlorine). Similarly, Paschim Banga's dextrose injection, which is used to normalise blood sugar levels, and its sodium chloride injection, had sterility issues. Thirteen batches of Martin & Brown BioSciences' calcium and vitamin D3 tablets had description errors. Vivek Pharmachem's paracetamol and ciprofloxacin hydrochloride tablets had description and dissolution issues respectively. Safe Care Life Sciences's mecobalamin 2,500 mg injection, which is used for vitamin B12 supplementation, had 2.38 mg per ml of mecobalamin against the labelled claim of 2,500 mg per ml in its vial. Two batches of Oscar Remedies's ciprofloxacin & dexamethasone eye/ear drops had 943.33% more ciprofloxacin than the labelled amount. The full lists of NSQ drugs made by the CDSCO and state regulators can be found here and here respectively. The Wire is now on WhatsApp. Follow our channel for sharp analysis and opinions on the latest developments.
Time of India
4 days ago
- Time of India
CORONA Remedies acquires 7 brands from Bayer's pharma division in India
CORONA Remedies on Thursday said it has acquired seven brands from the pharmaceutical division of Bayer in India for an undisclosed sum. The acquisition includes brands in the cardiology segment (Noklot) and women's healthcare portfolio (Fostine, Luprofact, Menodac, Ovidac, Spye and Vageston) in the Indian market , the company said in a statement. Explore courses from Top Institutes in Select a Course Category Public Policy Artificial Intelligence Product Management Digital Marketing Cybersecurity Technology MBA CXO Healthcare Others Data Science Leadership PGDM Design Thinking healthcare Operations Management Data Analytics Data Science Project Management others Management MCA Finance Degree Skills you'll gain: Economics for Public Policy Making Quantitative Techniques Public & Project Finance Law, Health & Urban Development Policy Duration: 12 Months IIM Kozhikode Professional Certificate Programme in Public Policy Management Starts on Mar 3, 2024 Get Details Skills you'll gain: Duration: 12 Months IIM Calcutta Executive Programme in Public Policy and Management Starts on undefined Get Details Through the acquisition, the company said it is entering the anti-platelet monotherapy segment while also increasing presence in the cardiology domain.
